Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
10.90
+0.03 (0.28%)
Dec 19, 2025, 9:30 AM EST - Market open
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $94.88M in the quarter ending September 30, 2025, with 17.67% growth. This brings the company's revenue in the last twelve months to $330.51M, up 26.73% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.
Revenue (ttm)
$330.51M
Revenue Growth
+26.73%
P/S Ratio
4.02
Revenue / Employee
$816,084
Employees
405
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 277.25M | 44.96M | 19.36% |
| Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
| Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
| Dec 31, 2021 | 439.44M | 392.89M | 844.00% |
| Dec 31, 2020 | 46.55M | 11.33M | 32.18% |
| Dec 31, 2019 | 35.22M | 27.02M | 329.60% |
| Dec 31, 2018 | 8.20M | 7.87M | 2,407.03% |
| Dec 31, 2017 | 327.00K | -10.72M | -97.04% |
| Dec 31, 2016 | 11.04M | 6.99M | 172.67% |
| Dec 31, 2015 | 4.05M | -6.98M | -63.29% |
| Dec 31, 2014 | 11.03M | -219.00K | -1.95% |
| Dec 31, 2013 | 11.25M | 1.54M | 15.82% |
| Dec 31, 2012 | 9.71M | -11.90M | -55.06% |
| Dec 31, 2011 | 21.61M | -2.34M | -9.75% |
| Dec 31, 2010 | 23.95M | -16.37M | -40.60% |
| Dec 31, 2009 | 40.32M | 3.22M | 8.69% |
| Dec 31, 2008 | 37.09M | 23.00M | 163.21% |
| Dec 31, 2007 | 14.09M | 9.25M | 190.76% |
| Dec 31, 2006 | 4.85M | -9.81M | -66.93% |
| Dec 31, 2005 | 14.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DVAX News
- 4 weeks ago - Dynavax to Participate at the 8th Annual Evercore Healthcare Conference - PRNewsWire
- 6 weeks ago - Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 6 weeks ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 2 months ago - Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 - PRNewsWire
- 2 months ago - Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial - PRNewsWire
- 2 months ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha
- 4 months ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire